Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

NWG

Navigating NatWest – A Stock Overview

It's been a great afternoon session for NatWest investors, who saw their shares rise 1.9% to a price of $13.61 per share. At these higher prices, is the company still fairly valued? If you are thinking about investing, make sure to check the company's fundamentals before making a decision.

a Decline in Expected Earnings Clouds Its Value Outlook but Priced at a Premium:

NatWest Group plc, together with its subsidiaries, provides banking and financial products and services to personal, commercial, corporate, and institutional customers in the United Kingdom and internationally. The company belongs to the Finance sector, which has an average price to earnings (P/E) ratio of 15.92 and an average price to book (P/B) ratio of 1.78. In contrast, NatWest has a trailing 12 month P/E ratio of 9.0 and a P/B ratio of 2.64.

NatWest has moved 67.0% over the last year compared to 12.3% for the S&P 500 — a difference of 54.7%. NatWest has a 52 week high of $13.61 and a 52 week low of $7.8.

Positive Cash Flows and a Highly Leveraged Balance Sheet:

2019 2020 2021 2022 2023 2024
Revenue (M) $18,163 $13,447 $12,702 $16,574 $25,382 $29,323
Interest Income (M) $3,328 $2,322 $1,699 $2,795 $9,977 $13,912
Operating Margins 15% -1% 4% -1% 2% 0%
Net Margins 21% -3% 26% 22% 18% 16%
Net Income (M) $3,800 -$434 $3,312 $3,595 $4,632 $4,811
Depreciation & Amort. (M) $1,218 $913 $923 $833 $934 $1,058
Diluted Shares (M) 12,095 12,130 11,468 9,787 8,992 8,332
Earnings Per Share $0.26 -$0.07 $0.27 $0.34 $0.48 $0.53
Free Cash Flow (M) -$3,079 $29,095 $53,684 -$43,597 -$17,438 $1,772
Total Debt (M) $337,636 $370,154 $369,719 $376,697 $391,584 $409,672
Net Debt / EBITDA 59.54 280.63 130.29 302.28 180.28 255.3

NatWest has weak net margins with a stable trend, positive cash flows, and a highly leveraged balance sheet.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS